Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323534336> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4323534336 endingPage "565" @default.
- W4323534336 startingPage "555" @default.
- W4323534336 abstract "To provide real-word evidence of patients with SCD initiating crizanlizumab, their use of other SCD treatments, and crizanlizumab treatment patterns.Using IQVIA's US-based, Longitudinal Patient-Centric Pharmacy and Medical Claims Databases patients with a diagnosis of SCD between November 1, 2018, and April 30, 2021, and ≥1 claim for crizanlizumab (date of first claim = index date) between November 1, 2019, and January 31, 2021 who were ≥16 years of age, and had ≥12 months of pre-index data were selected for analysis. Two cohorts were identified based on available follow-up time (3- and 6-month cohorts). Patient characteristics were reported along with pre- and post-index SCD treatments and crizanlizumab treatment patterns (e.g. total doses received, gap-days between doses, days on therapy, discontinuation, and restarts).540 patients met the base inclusion criteria (345 in the 3-month cohort and 262 in the 6-month cohort. Most patients (64%) were female with a mean (SD) age of 35 (12) years overall. Concomitant hydroxyurea use was observed in 19-39% of patients, while concomitant L-glutamine use was observed for 4-8% of patients. 85% of 3-month cohort patients received at least two doses of crizanlizumab, while 66% of the 6-month cohort received at least 4 doses of crizanlizumab. The median number of gap days between doses was 1 or 2.66% of patients who receive crizanlizumab receive at least 4 doses within 6-months. The low median number of gap days suggests high adherence." @default.
- W4323534336 created "2023-03-09" @default.
- W4323534336 creator A5004354044 @default.
- W4323534336 creator A5008849853 @default.
- W4323534336 creator A5012312377 @default.
- W4323534336 creator A5038320767 @default.
- W4323534336 creator A5065776456 @default.
- W4323534336 creator A5069708457 @default.
- W4323534336 creator A5077569956 @default.
- W4323534336 creator A5082001661 @default.
- W4323534336 date "2023-03-11" @default.
- W4323534336 modified "2023-10-14" @default.
- W4323534336 title "Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy" @default.
- W4323534336 cites W183015654 @default.
- W4323534336 cites W2018519248 @default.
- W4323534336 cites W2037439664 @default.
- W4323534336 cites W2045690184 @default.
- W4323534336 cites W2084545751 @default.
- W4323534336 cites W2088288415 @default.
- W4323534336 cites W2559643145 @default.
- W4323534336 cites W2794619359 @default.
- W4323534336 cites W2898014977 @default.
- W4323534336 cites W2900258767 @default.
- W4323534336 cites W2954363824 @default.
- W4323534336 cites W3036697233 @default.
- W4323534336 cites W4225352713 @default.
- W4323534336 doi "https://doi.org/10.1080/03007995.2023.2185391" @default.
- W4323534336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36883332" @default.
- W4323534336 hasPublicationYear "2023" @default.
- W4323534336 type Work @default.
- W4323534336 citedByCount "0" @default.
- W4323534336 crossrefType "journal-article" @default.
- W4323534336 hasAuthorship W4323534336A5004354044 @default.
- W4323534336 hasAuthorship W4323534336A5008849853 @default.
- W4323534336 hasAuthorship W4323534336A5012312377 @default.
- W4323534336 hasAuthorship W4323534336A5038320767 @default.
- W4323534336 hasAuthorship W4323534336A5065776456 @default.
- W4323534336 hasAuthorship W4323534336A5069708457 @default.
- W4323534336 hasAuthorship W4323534336A5077569956 @default.
- W4323534336 hasAuthorship W4323534336A5082001661 @default.
- W4323534336 hasBestOaLocation W43235343361 @default.
- W4323534336 hasConcept C126322002 @default.
- W4323534336 hasConcept C187212893 @default.
- W4323534336 hasConcept C2778715236 @default.
- W4323534336 hasConcept C2779384505 @default.
- W4323534336 hasConcept C71924100 @default.
- W4323534336 hasConcept C72563966 @default.
- W4323534336 hasConceptScore W4323534336C126322002 @default.
- W4323534336 hasConceptScore W4323534336C187212893 @default.
- W4323534336 hasConceptScore W4323534336C2778715236 @default.
- W4323534336 hasConceptScore W4323534336C2779384505 @default.
- W4323534336 hasConceptScore W4323534336C71924100 @default.
- W4323534336 hasConceptScore W4323534336C72563966 @default.
- W4323534336 hasIssue "4" @default.
- W4323534336 hasLocation W43235343361 @default.
- W4323534336 hasLocation W43235343362 @default.
- W4323534336 hasOpenAccess W4323534336 @default.
- W4323534336 hasPrimaryLocation W43235343361 @default.
- W4323534336 hasRelatedWork W1984309643 @default.
- W4323534336 hasRelatedWork W2106653639 @default.
- W4323534336 hasRelatedWork W2219852335 @default.
- W4323534336 hasRelatedWork W2466043692 @default.
- W4323534336 hasRelatedWork W2470410461 @default.
- W4323534336 hasRelatedWork W2603773853 @default.
- W4323534336 hasRelatedWork W2621229660 @default.
- W4323534336 hasRelatedWork W2791050137 @default.
- W4323534336 hasRelatedWork W3040203698 @default.
- W4323534336 hasRelatedWork W4221070417 @default.
- W4323534336 hasVolume "39" @default.
- W4323534336 isParatext "false" @default.
- W4323534336 isRetracted "false" @default.
- W4323534336 workType "article" @default.